Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,494.14 -7.51 -0.05%
S&P 500 1,878.34 2.95 0.16%
NASDAQ 4,137.82 10.85 0.26%
Ticker Volume Price Price Delta
STOXX 50 3,171.08 -4.89 -0.15%
FTSE 100 6,684.33 9.59 0.14%
DAX 9,483.95 -60.24 -0.63%
Ticker Volume Price Price Delta
NIKKEI 14,404.99 -141.28 -0.97%
TOPIX 1,164.90 -8.91 -0.76%
HANG SENG 22,562.80 53.16 0.24%

ARIAD to Present at Upcoming Investor Conferences



  ARIAD to Present at Upcoming Investor Conferences

34th Annual Goldman Sachs Global Healthcare Conference William Blair 33rd
Annual Growth Stock Conference 2013

Business Wire

CAMBRIDGE, Mass. -- June 4, 2013

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will
provide an overview of the Company’s business at two upcoming investor
conferences being held next week:

  * The William Blair Growth Stock Conference in Chicago. Timothy P. Clackson,
    Ph.D., president of research and development and chief scientific officer,
    will present on Tuesday, June 11 at 8:10 a.m. (CT).
  * The Goldman Sachs 34th Annual Global Healthcare Conference in Rancho Palos
    Verdes, CA. Harvey J. Berger, M.D., chairman and chief executive officer,
    will present on Tuesday, June 11 at 2:40 p.m. (PT)

Both presentations will be webcast live and can be accessed by visiting the
investor relations section of the Company's website at
http://www.ariad.com/investor. A replay of the presentation will also be
available and archived on the site for three weeks.

About ARIAD

ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and
Lausanne, Switzerland, is an integrated global oncology company focused on
transforming the lives of cancer patients with breakthrough medicines. ARIAD
is working on new medicines to advance the treatment of various forms of
chronic and acute leukemia, lung cancer and other difficult-to-treat cancers.
ARIAD utilizes computational and structural approaches to design
small-molecule drugs that overcome resistance to existing cancer medicines.
For additional information, visit http://www.ariad.com or follow ARIAD on
Twitter (@ARIADPharm).

Contact:

ARIAD Pharmaceuticals, Inc.
For Investors
Kendra Adams, 617-503-7028
Kendra.adams@ariad.com
or
For Media
Liza Heapes, 617-621-2315
Liza.heapes@ariad.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement